The Speak Foundation is hosting an important webinar with ML BIO SOLUTIONS. ML BIO SOLUTIONS will present “A Promising New Oral Treatment for LGMD2I: An Update on the Development of BBP-418 (Ribitol).” Sign up at: https://us02web.zoom.us/…/register/WN_zz63FN67TLqhYjC6kVRbyw.
October 9, 2020; Time: 2-4 pm Eastern Time
ML Bio Solutions is advancing the first-ever oral treatment for LGMD2I – BBP-418 (Ribitol). This treatment may enhance, and partially compensate for, diminished muscle function caused by the genetic driver of the disease. Join us to learn more about this treatment, the drug development process, and the status of the BBP-418 clinical studies.
Our panelists are Douglas Sproule, MD (Chief Medical Officer, ML Bio Solutions) and Nicholas Johnson, MD (Principle Investigator for the BBP-418 Lead-in Study).
The webinar, hosted by the Speak Foundation, is free and open to patients, family members and interested others.